Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eisai's sales of its Alzheimer's disease therapy Leqembi have disappointed analysts, leading the company to lower its fiscal 2024 guidance. The underwhelming sales are attributed to barriers such as coverage, infusion centers, and time to diagnosis. In other news, Pfizer has made a $1 billion commitment in China to boost innovation and target the Chinese market, while AstraZeneca's China head has been taken into custody by Chinese authorities for reasons that remain unclear. There is also a dispute between Lilly and Novo over Catalent's GLP-1 work, as regulators review Novo Holdings' buyout of Catalent and the work the contract drug manufacturer may or may not be performing for Eli Lilly remains contentious.Additionally, a gene therapy webinar on successful preparation for scaling gene therapy processes is highlighted. Other news includes the impact of a Trump victory on the biopharma industry, cell therapy biotechs shifting focus to autoimmune expertise, and updates on Lilly's Q3 performance and more.
View all episodes
